Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

THF-γ2, a thymic hormone, increases immunocompetence and survival in 5-fluorouracil-treated mice bearing MOPC-315 plasmacytoma

Summary

The effect of the thymic hormone, THF-γ2, on the immunocompetence of 5-fluorouracil (5-FU)-treated BALB/c mice, bearing MOPC-315 tumor, was examined. Treatment of noninoculated or tumor-bearing mice with THF-γ2 after 5-FU injection, resulted in an increase in the antibody response to sheep red blood cells and in the allogeneic response in spleen cell cultures and had no effect on the concanavalin-A-induced interleukin-2 secretion beyond that caused by 5-FU alone. Treatment with either 5-FU alone or 5-FU and THF-γ2 resulted in restoration to normal values of Lytl- and L3T4-positive populations in tumor-bearing mice. THF-γ2 prolonged the survival time of mice bearing MOPC-315 tumor beyond that observed in mice treated with 5-FU alone.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Ben-Efraim S, Bocian RC, Mokyr MB, Dray S (1983) Increase in effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol Immunother 15: 101

  2. 2.

    Ben-Efraim S, Shoval S, Ophir R (1986a) The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma. Cancer Immunol Immunother 22: 43

  3. 3.

    Ben-Efraim S, Shoval S, Gal T, Ophir R (1986b) Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity. Anticancer Res 6: 801

  4. 4.

    Bocian CB, Ben-Efraim S, Dray S, Mokyr MB (1984) Melphalan mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 18: 41

  5. 5.

    Burstein Y, Buchner V, Pecht M, Trainin N (1988) THF-γ2: purification and amino acid sequence of an immunoregulatory peptide from calf thymus. Biochemistry 27: 4066

  6. 6.

    Cunningham AJ, Szenberg A (1968) Further improvements in the plaque technique for detecting single antibody forming cells. Immunology 14: 599

  7. 7.

    David M, Shohat B, Trainin N, Feuerman E (1980) Cell mediated immunity in patients with mycosis fungoides in clinical remission. Effect of thymic humoral factor on the immunocompetence of the lymphocytes. Cancer 46: 41

  8. 8.

    David M, Shohat B, Feuerman E, Trainin N (1980) B and T lymphocytes in lymphoproliferative diseases of the skin. Effect of a thymic hormone on the immunocompetence of thymocytes. Br J Dermatol 102: 145

  9. 9.

    Eipert EF, Adorini L, Couderc J (1978) A miniaturized in vitro diffusion culture system. J Immunol Methods 22: 283

  10. 10.

    Gillis S, Ferm MW, Ou W, Smith KA (1978) T-cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027

  11. 11.

    Globerson A, Rotter V, Nakamura I, Trainin N (1973) Thymus extracts induced differentation of thymus derived cells. In: Jankovic BD, Isakovic K (eds) Microenvironmental aspects of immunity. Plenum Publishing Co. N.Y., p 183

  12. 12.

    Hengst JCD, Mokyr MB, Dray S (1980) Importance of timing in cyclophosphamide therapy of MOPC-315 tumor bearing mice. Cancer Res 40: 2135

  13. 13.

    Hengst JCD, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41: 2163

  14. 14.

    Julius MH, Simpson E, Herzenberg LA (1973) A rapid method for the isolation of functional thymus derived murine lymphocytes. Eur J Immunol 3: 645

  15. 15.

    Kook AI, Yakir Y, Trainin N (1975) Isolation and partial chemical characterization of THF, a thymic hormone, involved in immune maturation of lymphoid cells. Cell Immunol 19: 151

  16. 16.

    Levey RH, Trainin N, Law LW (1963) Evidence for function of thymus tissue in diffusion chambers implanted in neonatally thymectomized mice. J Natl Cancer Inst 31: 199

  17. 17.

    Merrifield RB (1963) The solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85: 2149

  18. 18.

    Mokyr MB, Colvin M, Dray S (1985) Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Int J Immunopharmacol 7: 111

  19. 19.

    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55

  20. 20.

    Osawa M, Diamanstein T (1984) A rat monoclonal antibody that binds specifically the mouse T lymphoblasts and inhibits IL-2 receptor functions: a putative anti-IL-2 receptor antibody. J Immunol 132: 2445

  21. 21.

    Rotter V, Globerson A. Nakamura I, Trainin N (1973) Studies on characterization of the lymphoid target cell for activity of a thymus humoral factor. J Exp Med 138: 130

  22. 22.

    Rotter V, Trainin N (1977) Effect of thymic hormone on the response of different lymphoid cell populations to T-mitogens. Isr J Med Sci 13: 363

  23. 23.

    Smith KA, Cantrell (1985) A Interleukin 2 regulates its own receptors. Proc Natl Acad Sci USA 32: 864

  24. 24.

    Trainin N, Small M, Globerson A (1969) Immunocompetence of spleen cells from neonatally thymectomized mice conferred in vitro by a syngeneic thymus extract. J Exp Med 130: 765

  25. 25.

    Trainin N, Kook AI, Umiel T, Albala M (1975) The nature and mechanism of stimulation of immune responsiveness by thymus extracts. Ann NY Acad Sci 249: 349

  26. 26.

    Trainin N, Zaizov R, Pecht M, Shohat B, Yakir Y (1980) The role of THF in immune modulation in patients receiving antineoplastic chemotherapy. In: Serrou B, Rosenfeld C (eds) International symposium on new trends in human immunology and cancer immunotherapy. Doin Editeurs, Paris, p 727

  27. 27.

    Trainin N, Handzel ZT, Pecht M (1985) Biological and clinical properties of THF. Thymus 7: 137

  28. 28.

    Trainin N, Burstein Y, Ben Efraim S, Goebel FD and Handzel ZT (1986) The use of the THF, a thymic hormone, for immunomodulation in cancer and AIDS. In: Novel approaches in cancer therapy. Lectures and Symposia 14th Int. Cancer Congr. Lapis/Eckhardt (eds) Budapest Vol. 5, p 253

  29. 29.

    Umiel T, Trainin N (1975) Increased reactivity of responding cells in the mixed lymphocyte reaction by a thymic humoral factor. Eur J Immunol 5: 85

  30. 30.

    Zaizov R, Vogel R, Wolach B, Cohen IJ, Varsano I, Shohat B, Handzel ZT, Rotter V, Yakir Y, Trainin N (1979) The effect of THF in lymphoproliferative and myeloproliferative diseases in children. Ann NY Acad Sci 332: 172

  31. 31.

    Zaizov R, Vogel R, Cohen IJ, Dvir A, Shohat B, Umiel T, Pecht M, Trainin N (1980) The immunomodulatory effect of THF in children with acute myelogenous leukemia. In: Serrou B, Rosenfeld C (eds) International symposium on new trends in human immunology and cancer immunotherapy. Doin Editeurs, Paris, p 807

Download references

Author information

Correspondence to Rachel Ophir.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ophir, R., Pecht, M., Halperin, D. et al. THF-γ2, a thymic hormone, increases immunocompetence and survival in 5-fluorouracil-treated mice bearing MOPC-315 plasmacytoma. Cancer Immunol Immunother 30, 119–125 (1989). https://doi.org/10.1007/BF01665963

Download citation

Keywords

  • Cell Culture
  • Blood Cell
  • Cancer Research
  • Survival Time
  • Antibody Response